Melatonin for Anti-Inflammation: What the Research Says

Overview

Inflammation is a hallmark of numerous chronic diseases—from diabetes and metabolic syndrome to cardiovascular disease and autoimmune conditions. While acute inflammation is a protective response, chronic systemic inflammation drives tissue damage, accelerates aging, and increases disease risk. Traditional anti-inflammatory approaches rely on pharmaceutical interventions, but emerging research suggests that melatonin, best known as a sleep hormone, may offer a potent and accessible complement to conventional strategies.

Melatonin is a neurohormone produced by the pineal gland that regulates sleep-wake cycles and circadian rhythms. Beyond its well-documented sleep benefits, mounting evidence reveals that melatonin possesses powerful anti-inflammatory properties—reducing key inflammatory markers like C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) across multiple human studies. This article synthesizes the research on melatonin's anti-inflammatory effects, examining the mechanisms, clinical evidence, and practical considerations for use.

How Melatonin Affects Anti-Inflammation

Melatonin reduces inflammation through multiple, complementary biological pathways:

Free Radical Scavenging and Antioxidant Activity

Melatonin acts as a direct free radical scavenger, neutralizing reactive oxygen species (ROS) that trigger inflammatory cascades. Unlike most antioxidants, melatonin crosses the blood-brain barrier and penetrates mitochondrial membranes, protecting these critical cellular structures from oxidative damage. Additionally, melatonin upregulates endogenous antioxidant enzymes—including superoxide dismutase (SOD) and glutathione peroxidase (GPx)—amplifying the body's natural antioxidant defenses. This increased total antioxidant capacity (TAC) reduces oxidative stress, a primary driver of chronic inflammation.

NF-κB Pathway Inhibition

A central mechanism of melatonin's anti-inflammatory effect is suppression of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), a transcription factor that initiates pro-inflammatory gene expression. By inhibiting NF-κB activation, melatonin directly suppresses the production of inflammatory cytokines including TNF-α, IL-6, and IL-1β. This represents a fundamental brake on the inflammatory cascade at the genetic level.

Circadian Rhythm Restoration

Circadian rhythm disruption—common in modern life due to shift work, jet lag, and irregular sleep—directly promotes chronic inflammation through dysregulation of immune function and inflammatory signaling. Melatonin restores circadian-regulated immune homeostasis, re-synchronizing inflammatory processes that become chaotic when circadian rhythms deteriorate. This is particularly relevant because immune cells follow circadian patterns; disrupting these patterns shifts immune function toward a pro-inflammatory state.

Mitochondrial Protection

Within mitochondria, melatonin prevents cytochrome c release and inhibits mitochondrial-triggered inflammatory cascades. By stabilizing mitochondrial function, melatonin reduces the leak of inflammatory mediators from damaged mitochondria—a process now recognized as central to chronic inflammation in aging and metabolic disease.

Sirt1 Upregulation

Melatonin activates Sirt1 (sirtuin 1), a NAD-dependent deacetylase that suppresses inflammatory signaling and promotes cellular stress resistance. This activation provides additional anti-inflammatory signaling independent of antioxidant mechanisms.

What the Research Shows

The evidence for melatonin's anti-inflammatory effects in humans is robust, supported by multiple large meta-analyses and numerous randomized controlled trials (RCTs) across diverse populations.

Meta-Analytic Evidence: The Gold Standard

A comprehensive meta-analysis of 63 RCTs published in 2025 represents the most extensive synthesis of melatonin's effects on inflammatory markers. Results were striking:

• C-reactive protein (CRP) decreased by 0.59 mg/L (95% CI: -0.94, -0.23)
• TNF-α decreased by 1.61 pg/mL (95% CI: -2.31, -0.90)
• IL-6 decreased by 6.43 pg/mL (95% CI: -10.72, -2.15)

These reductions are clinically meaningful. CRP is a major cardiovascular risk factor; a reduction of 0.59 mg/L translates to approximately 25-30% improvement in patients with baseline elevations. TNF-α and IL-6 are key orchestrators of systemic inflammation implicated in diabetes, cardiovascular disease, and neuroinflammation.

An earlier meta-analysis of 13 studies (n=749 participants) found even larger IL-6 reductions:

• TNF-α decreased by 2.24 pg/ml (95% CI: -3.45, -1.03; p<0.001)
• IL-6 decreased by 30.25 pg/ml (95% CI: -41.45, -19.06; p<0.001)

The variation between meta-analyses reflects differences in included studies and populations, but the direction of effect is consistent: melatonin reliably reduces pro-inflammatory cytokines.

Diabetes-Specific Evidence

Diabetic patients represent a population with chronically elevated inflammatory markers. A meta-analysis of 14 RCTs (n=823 people with diabetes) demonstrated that melatonin reduced:

• CRP (standardized mean difference [SMD]=-0.75; 95% CI: -1.37, -0.12)
• TNF-α (SMD=-0.40; 95% CI: -0.64, -0.15)
• IL-1β (SMD=-0.75; 95% CI: -1.03, -0.47)
• IL-6 (SMD=-0.79; 95% CI: -1.07, -0.51)

These effects are particularly important in diabetes because chronic inflammation accelerates vascular complications, neuropathy, and nephropathy. By reducing inflammatory cytokines, melatonin may slow diabetic complications.

Individual RCT Evidence

While meta-analyses provide population-level estimates, individual RCTs confirm these effects in specific populations:

Chronic Kidney Disease with Diabetes: A double-blind RCT (n=41) administered 5 mg melatonin twice daily for 10 weeks to diabetic patients with chronic kidney disease. Results showed significant decreases in high-sensitivity CRP (hs-CRP), malondialdehyde (MDA), and total oxidative stress (TOS) compared to placebo, with no adverse effects reported.

Multiple Sclerosis: An RCT (n=27) in MS patients found that 3 mg melatonin daily for 12 weeks increased heart rate variability (a marker of autonomic health) while decreasing MDA and advanced oxidation protein products (AOPP)—both markers of oxidative stress that drive inflammatory damage in MS.

Metabolic Syndrome: Across multiple RCTs in patients with metabolic dysfunction (insulin resistance, dyslipidemia, hypertension), melatonin consistently reduced inflammatory markers alongside improvements in metabolic parameters. This is significant because metabolic inflammation (metaflammation) is a driver of obesity-related complications.

Mechanisms Confirmed in Human Studies

Human studies have directly measured the mechanistic pathways through which melatonin reduces inflammation:

• Increased total antioxidant capacity (TAC): Meta-analysis of 12 RCTs found melatonin increased TAC with a standardized mean difference of 0.76 (95% CI: 0.30, 1.21).
• Increased glutathione levels: Meta-analysis showed an SMD of 0.57 (95% CI: 0.32, 0.83), confirming upregulation of the body's master antioxidant.
• Reduced oxidative stress markers: Consistent decreases in MDA and other ROS-derived biomarkers across studies.

Dosing for Anti-Inflammation

Research on melatonin's anti-inflammatory effects has used a range of doses. Based on the published literature:

Standard Anti-Inflammatory Dosing:

• 2-10 mg daily appears effective, based on meta-analyses
• Most individual RCTs used 3-5 mg daily for anti-inflammatory benefits
• Some studies employed 10 mg daily without additional safety concerns, though morning grogginess is more common at higher doses

Duration:

• Anti-inflammatory benefits typically emerge within 2-4 weeks of consistent supplementation
• Longer-term studies (8-12 weeks) show sustained reductions in inflammatory markers, suggesting no tolerance develops
• At least 8-12 weeks of supplementation appears necessary to observe meaningful reductions in inflammatory biomarkers

Route of Administration:

• Oral (capsule/tablet): 0.5-5 mg once daily, typically taken 30-60 minutes before bedtime
• Sublingual: 0.5-3 mg once daily, absorbed rapidly under the tongue

The oral route is more practical for anti-inflammatory supplementation since melatonin's circadian and anti-inflammatory effects are complementary when dosed in the evening.

Dose-Response Considerations:

Interestingly, the anti-inflammatory benefits of melatonin appear to plateau or show diminishing returns at very high doses. Most evidence supports moderate doses (3-5 mg) rather than high-dose supplementation (>20 mg). This may reflect melatonin's biphasic effects—moderate doses enhance antioxidant defenses and suppress NF-κB, while very high doses may trigger different receptor signaling or metabolic pathways with reduced anti-inflammatory benefit.

Side Effects to Consider

Melatonin has an excellent short-term safety profile and is among the most widely used sleep supplements globally. However, several considerations apply when using melatonin specifically for anti-inflammation:

Common Side Effects:

• Morning grogginess or next-day sedation, particularly at doses above 3 mg
• Vivid or unusual dreams (may reflect enhanced sleep depth rather than toxicity)
• Headache, especially with higher doses or prolonged use
• Mild nausea or gastrointestinal discomfort
• Dizziness or lightheadedness shortly after administration

These effects are generally mild and dose-dependent. Starting with lower doses (2-3 mg) and titrating upward allows tolerance assessment.

Special Populations:

• Pregnant or breastfeeding individuals: Exercise caution; melatonin crosses the placenta and is excreted in breast milk. Medical consultation is advisable.
• Autoimmune conditions: Melatonin modulates immune function and may theoretically exacerbate certain autoimmune diseases (though anti-inflammatory effects might help others). Individuals with lupus, rheumatoid arthritis, or other autoimmune disorders should consult their healthcare provider.
• Children: Use melatonin with caution; long-term effects in developing brains remain understudied.

Regulatory Status:

Melatonin is available over-the-counter in the United States and many countries, but is classified as a prescription medication in the UK, Germany, and Australia for doses above 2 mg. This regulatory variation reflects differing risk-benefit assessments; higher doses warrant medical supervision in these jurisdictions.

Long-Term Use:

While short-term safety is well-established, long-term effects of pharmacological doses (exceeding physiological levels) remain incompletely studied. The available evidence does not suggest major safety concerns with years of use at moderate doses, but extended supplementation should ideally be monitored by a healthcare provider.

The Bottom Line

Melatonin represents a well-researched, accessible, and safe option for reducing systemic inflammation. Evidence from 63 RCTs demonstrates that melatonin supplementation consistently reduces inflammatory markers including C-reactive protein, TNF-α, and IL-6—with clinically meaningful effect sizes. The anti-inflammatory effect is most robust in populations with chronic disease (diabetes, metabolic syndrome, multiple sclerosis), where inflammation is already elevated, though mechanistic studies suggest benefits should extend to other inflammatory conditions.

The proposed mechanisms—free radical scavenging, antioxidant enzyme upregulation, NF-κB inhibition, circadian rhythm restoration, and mitochondrial protection—are biologically sound and confirmed in human research. Dosing of 3-5 mg daily for 8-12 weeks appears optimal based on available evidence, with good tolerability and safety.

However, important limitations remain. Most human evidence derives from disease-specific populations; broader application to healthy individuals requires extrapolation. Dose-response relationships are incompletely characterized, and optimal dosing for different inflammatory conditions remains unclear. Additionally, individual RCTs are often modest in size (n=12-41); the strongest evidence comes from meta-analyses rather than single large-scale trials.

For individuals seeking to reduce inflammation through supplementation, melatonin offers a rational evidence-based choice, particularly when combined with lifestyle modifications (sleep optimization, stress management, regular exercise, anti-inflammatory diet). Those with autoimmune conditions, pregnant or breastfeeding individuals, or anyone on medications should consult their healthcare provider before supplementing.

Disclaimer: This article is educational and does not constitute medical advice. Melatonin supplementation should not replace conventional medical treatment for inflammatory conditions. Always consult with a qualified healthcare provider before starting any new supplement, particularly if you have underlying health conditions or take medications.